Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of 43.79 million. The enterprise value is 72.78 million.
| Market Cap | 43.79M |
| Enterprise Value | 72.78M |
Important Dates
The last earnings date was Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.83% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 43.94M |
Valuation Ratios
The trailing PE ratio is 9.18.
| PE Ratio | 9.18 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.48, with an EV/FCF ratio of 30.56.
| EV / Earnings | 15.25 |
| EV / Sales | 1.28 |
| EV / EBITDA | 7.48 |
| EV / EBIT | 13.70 |
| EV / FCF | 30.56 |
Financial Position
The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.55.
| Current Ratio | 2.50 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 3.45 |
| Debt / FCF | 15.04 |
| Interest Coverage | 1.51 |
Financial Efficiency
Return on equity (ROE) is 7.68% and return on invested capital (ROIC) is 3.65%.
| Return on Equity (ROE) | 7.68% |
| Return on Assets (ROA) | 3.22% |
| Return on Capital (ROIC) | 3.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -23.50% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.63 |
| Relative Strength Index (RSI) | 47.38 |
| Average Volume (20 Days) | 18,603 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of 60.58 million and earned 4.77 million in profits. Earnings per share was 0.05.
| Revenue | 60.58M |
| Gross Profit | 22.07M |
| Operating Income | 5.66M |
| Pretax Income | 3.32M |
| Net Income | 4.77M |
| EBITDA | 10.18M |
| EBIT | 5.66M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 4.91 million in cash and 35.81 million in debt, giving a net cash position of -30.91 million.
| Cash & Cash Equivalents | 4.91M |
| Total Debt | 35.81M |
| Net Cash | -30.91M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 65.18M |
| Book Value Per Share | 0.72 |
| Working Capital | 29.99M |
Cash Flow
In the last 12 months, operating cash flow was 7.92 million and capital expenditures -5.53 million, giving a free cash flow of 2.38 million.
| Operating Cash Flow | 7.92M |
| Capital Expenditures | -5.53M |
| Free Cash Flow | 2.38M |
| FCF Per Share | n/a |
Margins
Gross margin is 36.44%, with operating and profit margins of 9.35% and 7.88%.
| Gross Margin | 36.44% |
| Operating Margin | 9.35% |
| Pretax Margin | 5.49% |
| Profit Margin | 7.88% |
| EBITDA Margin | 16.81% |
| EBIT Margin | 9.35% |
| FCF Margin | 3.93% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.83% |
| Shareholder Yield | -1.83% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 1.57. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.57 |
| Piotroski F-Score | n/a |